Analyst Price Targets — GDRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 6:08 pm | Michael Cherny | Leerink Partners | $3.00 | $2.02 | StreetInsider | GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners |
| January 22, 2026 6:00 am | Glen Santangelo | Jefferies | $2.75 | $2.58 | StreetInsider | Jefferies Downgrades GoodRx Holdings Inc. (GDRX) to Hold |
| December 18, 2025 12:54 pm | — | Morgan Stanley | $4.00 | $2.78 | TheFly | GoodRx price target lowered to $4 from $5 at Morgan Stanley |
| December 8, 2025 9:14 pm | — | Barclays | $3.00 | $2.72 | TheFly | GoodRx initiated with an Underweight at Barclays |
| August 11, 2025 11:01 am | George Hill | Deutsche Bank | $6.00 | $3.47 | TheFly | GoodRx price target lowered to $6 from $8 at Deutsche Bank |
| June 10, 2024 5:32 am | Craig Hettenbach | Morgan Stanley | $9.50 | $8.55 | TheFly | GoodRx price target raised to $9.50 from $7 at Morgan Stanley |
| May 23, 2024 1:50 am | Mark Mahaney | RBC Capital | $10.00 | $7.20 | StreetInsider | RBC Capital Upgrades GoodRx Holdings Inc. (GDRX) to Outperform |
| May 16, 2024 2:46 pm | Stephanie Davis | Barclays | $9.00 | $8.06 | StreetInsider | Barclays Reiterates Overweight Rating on GoodRx Holdings Inc. (GDRX) |
| May 16, 2024 5:57 am | Aaron Kessler | Raymond James | $10.00 | $7.27 | StreetInsider | Raymond James Upgrades GoodRx Holdings Inc. (GDRX) to Outperform |
| April 10, 2024 12:10 pm | Scott Schoenhaus | BOCOM International Holdings Company | $9.00 | $6.92 | Benzinga | GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings |
Latest News for GDRX
GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
The prescription experience has started to resemble other parts of digital commerce: shoppers want clear pricing, fewer handoffs and a quicker path from decision to fulfillment. That push toward self-service framed GoodRx's fourth-quarter earnings discussion Thursday (Feb.
While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights Revenue of $194.8 million Net income of $5.4 million; Net income margin of 2.8% Adjusted Net Income1 of $29.0 million;…
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GDRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.